Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease.
Iams WT, Kopparapu PR, Yan Y, Muterspaugh A, Zhao Z, Chen H, Cann C, York S, Horn L, Ancell K, Wyman K, Bertucci C, Shaffer T, Hodsdon LA, Garg K, Hosseini SA, Lim LP, Lovly CM.
Iams WT, et al. Among authors: wyman k.
JTO Clin Res Rep. 2020 Mar 12;1(2):100024. doi: 10.1016/j.jtocrr.2020.100024. eCollection 2020 Jun.
JTO Clin Res Rep. 2020.
PMID: 34589931
Free PMC article.